235.89
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $235.89, with a volume of 271.13K.
It is up +0.77% in the last 24 hours and up +12.11% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$234.40
Open:
$233.94
24h Volume:
271.13K
Relative Volume:
0.30
Market Cap:
$26.03B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
26.02
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
-0.60%
1M Performance:
+12.11%
6M Performance:
+14.95%
1Y Performance:
+31.39%
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DGX
Quest Diagnostics Inc
|
235.87 | 25.87B | 11.28B | 1.07B | 1.33B | 9.0657 |
|
TMO
Thermo Fisher Scientific Inc
|
586.82 | 217.52B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
202.01 | 142.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
313.46 | 44.67B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
IDXX
Idexx Laboratories Inc
|
543.38 | 43.41B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
148.76 | 41.95B | 7.23B | 1.41B | 1.09B | 4.979 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Simplicity Wealth LLC Acquires New Position in Quest Diagnostics Incorporated $DGX - MarketBeat
J.Safra Asset Management Corp Purchases New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
ABN AMRO Bank N.V. Takes $21.52 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Carol Devine Miller sells stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp - Investing.com South Africa
Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know - Yahoo Finance
T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A - Stock Titan
Assenagon Asset Management S.A. Acquires 4,334 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86 - MarketBeat
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q2 2026 Quest Diagnostics Inc Earnings Call Transcript - GuruFocus
Rep. Carol Miller's household sold Pfizer, Quest, Target, and U.S. Bancorp 521 days before disclosure - 24/7 Wall St.
Quest Diagnostics Keeps Quarterly Dividend at $0.86 per Share, Payable Oct. 21, to Shareholders of Record Oct. 6 - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend - marketscreener.com
Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on October 21, 2026 - marketscreener.com
Diversified Management Inc. Lowers Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
IVY LANE CAPITAL MANAGEMENT, LLC's Quest Diagnostics Inc(DGX) Holding History - GuruFocus
Quest Diagnostics Incorporated $DGX Holdings Trimmed by Empowered Funds LLC - MarketBeat
Quest Diagnostics Inc (DGX) Stock News Today - TradingKey
Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Quest Diagnostics (DGX) A Bargain Following Raised Guidance And Strong Quarterly Results? - Yahoo Finance
Quest Diagnostics (DGX) Stock May Be 32% Undervalued As Guidance Rises - Yahoo Finance
Arrowstreet Capital Limited Partnership Purchases New Shares in Quest Diagnostics Incorporated $DGX - marketbeat.com
Quest Diagnostics Incorporated $DGX Shares Bought by Eastern Bank - MarketBeat
Royal Bank of Canada Has $38.91 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates - The Globe and Mail
Bank of America Corp DE Acquires 129,964 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Cetera Investment Advisers Acquires 8,362 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
California State Teachers Retirement System Sells 5,763 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Alpine Woods Capital Investors LLC Cuts Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Sei Investments Co. Increases Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
PR News | On the Move: Quest Diagnostics Names Chokshi IR ChiefThu., Jul. 30, 2026 - O'Dwyer's PR
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics - morningstar.com
Quest Diagnostics Incorporated $DGX Shares Sold by Lazard Asset Management LLC - MarketBeat
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $248.86, Implies 6% Upside - TradingView
OMERS ADMINISTRATION Corp Buys 10,073 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Insider at DGX (NYSE: DGX) plans sale of 1,600 common shares - Stock Titan
JPMorgan Adjusts Price Target on Quest Diagnostics to $250 From $220, Maintains Neutral Rating - marketscreener.com
DGX|Quest Diagnostics Inc|Price:231.750|Chg%:+3.890 - TradingKey
EdgePoint Investment Group Inc. Buys 582,797 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc (DGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Quest Diagnostics orporated For: 28 July By Investing.com - Investing.com South Africa
Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
Quest Diagnostics (NYSE: DGX) SVP adds shares via dividend reinvestment plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP acquires 34.0000 shares via dividend reinvestment - Stock Titan
Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating - Moomoo
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Quest Diagnostics (DGX) Leads S&P 500 Healthcare Gainers with 8. - GuruFocus
Quest Diagnostics Incorporated (DGX) Stock forecasts - Yahoo Finance Singapore
Why Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting Buybacks - Yahoo Finance
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):